Changes in Beneficial Ownership · 4
Guardant Health, Inc.
GHNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
wk-form4_1785963927.xml
Filing details
- Report period
- 2026-08-04
- Issuer
- Guardant Health, Inc.
- Issuer CIK
- 0001576280
- Trading symbol
- GH
Reporting owner 1
- Name
- CLARK IAN T
- Reporting owner CIK
- 0001336504
- Relationship
- Director
- Address
- 3100 HANOVER STREET, PALO ALTO, CA, 94304
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | 2026-08-04 | M · Form 4 | 2,255 | A | 91.11 | 10,322 | I | By The Thornton-Clark Family Trust, J Thornton-Clark & I Clark TTE Account |
| Common Stock | 2026-08-04 | M · Form 4 | 6,833 | A | 50.57 | 17,155 | I | By The Thornton-Clark Family Trust, J Thornton-Clark & I Clark TTE Account |
| Common Stock | 2026-08-04 | S · Form 4 | 9,088 | D | 158.9816[F1] | 8,067 | I | By The Thornton-Clark Family Trust, J Thornton-Clark & I Clark TTE Account |
| Common Stock | 2026-08-04 | S · Form 4 | 5,092 | D | 158.8032[F2] | 2,975 | I | By The Thornton-Clark Family Trust, J Thornton-Clark & I Clark TTE Account |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- A
- Acquired
- I
- Indirect
- S · Form 4
- Sale on the market or privately
- D
- Disposed
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) | 91.11 | 2026-08-04 | M · Form 4 | 2,255 | D | 0 | [F3] | 2029-06-18 | Common Stock | 2,255 | 0 | D |
| Stock Option (Right to Buy) | 50.57 | 2026-08-04 | M · Form 4 | 6,833 | D | 0 | [F4] | 2035-06-18 | Common Stock | 6,833 | 0 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- D
- Direct
Footnotes
- F1
- Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $158.510 to $159.435. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.↩ 1
- F2
- Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $158.51 to $159.14. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.↩ 1
- F3
- The stock option vested in full on June 12, 2020.↩ 1
- F4
- The stock option vested in full on June 17, 2026.↩ 1
Signature 1
- Signed
- /s/ John G. Saia, as attorney-in-fact for Ian T. Clark
- Date
- 2026-08-05
Company context
Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer.